Onco Wiki / Drogue

Asciminib

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDDRUG-ASCIMINIB
TypeMédicament
Alias
ScemblixАсцимініб
Étatreviewed 2026-04-25 | pending_clinical_signoff
MaladiesDIS-CML
SourcesSRC-ELN-CML-2020 SRC-NCCN-MPN-2025

Faits sur les drogues

CatégorieInhibiteur BCR-ABL1 STAMP (Cible spécifique de la poche ABL Myristoyl; allostérique)
MécanismeAllosteric inhibitor binding the ABL1 myristoyl pocket — distinct from the ATP-binding site targeted by all classical TKIs (imatinib, dasatinib, nilotinib, bosutinib, ponatinib). This unique mechanism avoids cross-resistance with most ATP-site mutations including T315I (at higher dose 200 mg BID). First-in-class STAMP inhibitor; approved 3L+ for CML-CP after ≥2 prior TKIs (ASCEMBL trial) and for T315I-mutated CML.
Dose typiqueCML-CP after ≥2 prior TKIs (no T315I): 80 mg PO once daily OR 40 mg PO BID (with or without food, but consistency required; high-fat meal reduces exposure). T315I-positive CML-CP: 200 mg PO BID. Continue until progression / unacceptable toxicity.
Ukraine enregistréeFaux
NSZU rembourséFaux
Ukraine vérifiée pour la dernière fois2026-04-27

Notes

Pivotal: ASCEMBL (Réa et al., Blood 2021) phase-3 — asciminib 40 mg BID vs bosutinib 500 mg daily in CML-CP after ≥2 prior TKIs; MMR at 24 weeks 25.5% vs 13.2%. Vascular safety profile substantially better than ponatinib. T315I activity at higher dose (200 mg BID) per phase-1 (Hughes et al., NEJM 2019). Ukraine: NOT registered — access via named-patient import / EAP Novartis / cross-border. Dose-and-take consistency (with food vs without) matters: high-fat meal substantially reduces exposure. Lipase + ECG monitoring; vascular safety profile much better than ponatinib but cardiovascular events still observed.

Utilisé par

Protocole thérapeutique